torI Antibody

What is Toripalimab and how does it function as an immune checkpoint inhibitor?

Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd. It functions by binding to PD-1 and blocking its interaction with ligands PD-L1 and PD-L2 . This blockade prevents downstream signaling pathways that normally inhibit T cell activation, thereby recovering the anti-tumor immune response of T cells . The binding mechanism is primarily attributed to the heavy chain of toripalimab and the FG loop of PD-1 .

At the molecular level, toripalimab:

• Inhibits PD-1 expression on CD4+ and CD8+ T cells in a dose-dependent manner

• Achieves PD-1 receptor occupancy up to 90% at 1 mg/kg and 100% at 10 mg/kg in preclinical models

• Stimulates human T cell proliferation and increases IFN-γ and TNF-α secretion dose-dependently

How does toripalimab differ structurally and functionally from other PD-1 inhibitors like pembrolizumab?

Toripalimab exhibits distinct molecular and functional characteristics compared to pembrolizumab:

These molecular differences may explain why toripalimab has demonstrated clinical efficacy irrespective of PD-L1 status in multiple tumor types, whereas other PD-1 inhibitors typically show greater benefit in patients with high PD-L1 expression .

What is the immunogenicity profile of toripalimab and how does it impact clinical efficacy?

Toripalimab demonstrates relatively low immunogenicity in both animal models and clinical trials:

In preclinical studies, only 10% of cynomolgus monkeys developed anti-drug antibodies (ADAs) 28 days after first administration across various dosage groups (1, 10, and 75 mg/kg) .

In clinical trials:

• NCT03013101: 10.2% (13/128) of melanoma patients developed ADAs after treatment, with only one patient showing decreased plasma concentration

• NCT02857166: ADA detection varied by dosage: 33.3% (0.3 mg/kg), 42.9% (1 mg/kg), 16.7% (3 mg/kg), and 0% in both 10 mg/kg and 240 mg groups

• In combination therapy with HBM4003, 5.0% of participants developed treatment-induced ADAs against toripalimab, while 5.0% showed treatment-enhanced ADAs

Importantly, the presence of ADAs did not significantly impact the pharmacokinetic profiles or clinical efficacy of toripalimab in most patients . This low immunogenicity is advantageous for maintaining consistent drug exposure and therapeutic effect throughout treatment courses.

What mechanisms explain toripalimab's efficacy in PD-L1 negative tumors where other PD-1 inhibitors show limited benefit?

Toripalimab demonstrates efficacy regardless of PD-L1 status, which is distinct from other PD-1 inhibitors. This unique characteristic can be explained by several mechanisms:

How do tumor mutational burden and specific genetic alterations impact response to toripalimab treatment?

Genomic analysis using whole-exome sequencing from 394 tumor samples in the CHOICE-01 trial revealed important correlations between genetic features and toripalimab response:

• Tumor Mutational Burden (TMB):

  • Patients with high TMB showed significantly better PFS in the toripalimab arm (median PFS 13.1 vs. 5.5 months, interaction P=0.026)

  • This aligns with findings for other PD-1 inhibitors but appears more pronounced with toripalimab

• Focal adhesion-PI3K-Akt signaling pathway mutations:

  • Patients with mutations in this pathway achieved significantly better PFS and OS in the toripalimab arm (interaction P values ≤0.001)

  • This represents a potentially novel predictive biomarker specific to toripalimab

• Tumor microenvironment factors:

  • In the HBM4003/toripalimab combination study, baseline high Treg/CD4+ ratio in the tumor served as an independent predictive factor for treatment efficacy

  • Spatial analysis revealed a remarkable increase in T-cells within the tumor after treatment, particularly a significant elevation in CD8+ killer T-cells

These findings suggest that genomic profiling, particularly for specific pathway mutations and immune microenvironment characteristics, may help identify patients most likely to benefit from toripalimab treatment.

What pharmacodynamic changes occur in the tumor microenvironment following toripalimab administration?

Toripalimab induces several significant pharmacodynamic changes in the tumor microenvironment:

• T cell proliferation and activation:

  • Significant increases in proliferating Ki-67+CD8+ and Ki-67+CD4+ T cells observed after treatment

  • Complete PD-1 receptor occupancy (>80%) maintained on CD4+ and CD8+ T cells throughout treatment period in multiple dose cohorts

• Cytokine response:

  • Dose-dependent increases in serum IFN-γ and TNF-α levels

  • Enhanced IL-2 secretion that was more potent than pembrolizumab at equivalent concentrations

  • Toripalimab showed superior induction of multiple Th1 cytokines compared to pembrolizumab at 3.3 μg/mL concentration

• Tumor infiltration dynamics:

  • Multiplex immunofluorescence staining revealed remarkable increases in tumor-infiltrating T cells

  • Particularly significant elevation in CD8+ killer T cells within the tumor microenvironment

• Gene expression changes:

  • In ex vivo systems using dissociated tumor cells, toripalimab induced several unique genes in IFN-γ pathways

  • Enhanced IFN-γ signature with different kinetics of activation compared to other PD-1 inhibitors

These pharmacodynamic effects illustrate toripalimab's potent immunomodulatory activity and help explain its clinical efficacy across various tumor types.

What is the optimal dosing strategy for toripalimab in different cancer types and combination regimens?

Based on pharmacokinetic studies and clinical trials, the following dosing strategies have been established:

Monotherapy regimens:

• Standard recommended dose: 240 mg every 3 weeks (Q3W)

• In phase I trials, multiple dose levels (0.3, 1, 3, 10 mg/kg and 240 mg) were evaluated

• The 240 mg fixed dose showed comparable efficacy with lower immunogenicity (0% ADA development) compared to weight-based dosing

Combination therapy regimens:

• With chemotherapy: 240 mg Q3W for 4-6 cycles, followed by maintenance toripalimab 240 mg Q3W

• With HBM4003 (anti-CTLA-4): toripalimab 240 mg with HBM4003 0.3 mg/kg Q3W

• Maximum duration of maintenance treatment in some protocols is 2 years

Pharmacokinetic considerations:

• Serum half-life: 150-222 hours after single infusion; 188-525 hours after multi-dose infusions

• Steady-state trough concentrations at 3 mg/kg Q2W: 37.8 ± 17.5 μg/mL

• Complete PD-1 receptor occupancy (>80%) maintained throughout treatment period in most dose cohorts

The dosing strategy may need adjustment based on cancer type, combination agents, and patient factors, with 240 mg Q3W emerging as the standard dose across most indications.

How does toripalimab perform in clinical trials across different cancer types compared to other immunotherapies?

Toripalimab has demonstrated significant clinical benefits across multiple cancer types:

Nasopharyngeal Carcinoma (NPC):

• FDA approved for first-line treatment in combination with chemotherapy

• JUPITER-02 trial: Improved OS irrespective of PD-L1 status

• Unlike pembrolizumab, does not show vascular toxicity in NPC patients

Non-Small Cell Lung Cancer (NSCLC):

• CHOICE-01 trial: Significant improvement in both PFS (8.3 vs 5.6 months, HR=0.49) and OS (NR vs 17.1 months, HR=0.69)

• Efficacy observed regardless of PD-L1 status, including TPS <1% subgroup

Melanoma:

• First approved indication in China (2018) for unresectable or metastatic melanoma after prior systemic therapy

• In combination with axitinib, showed impressive results in metastatic mucosal melanoma

• Combined with HBM4003: ORR of 33.3% in anti-PD-1/PD-L1 treatment-naïve patients; 40% in mucosal melanoma subgroup

Other tumor types:

• Urothelial carcinoma: Approved in China (2021)

• Esophageal squamous cell carcinoma: JUPITER-06 trial showed improved OS irrespective of PD-L1 status

• Cholangiocarcinoma: Phase 1 US study showed ORR of 4.8% and DCR of 40.5%

Comparative advantages:

• Efficacy in PD-L1 negative tumors distinguishes toripalimab from other PD-1 inhibitors

• Higher binding affinity and more potent T cell activation may contribute to broader clinical activity

What are the patterns of immune-related adverse events with toripalimab and how do they compare with other PD-1 inhibitors?

Toripalimab demonstrates a safety profile generally consistent with the PD-1 inhibitor class, with some notable differences:

Incidence and severity of immune-related adverse events (irAEs):

• JUPITER-02: irAEs affected 54.1% of toripalimab patients vs 21.7% in placebo arm

• Grade ≥3 irAEs: 9.6% with toripalimab vs 1.4% with placebo

• US Phase 1 study: Grade ≥3 irAEs occurred in 4.2% of patients (7/166)

• Combination with HBM4003: 12.5% experienced grade 3 irAEs; no grade 4-5 irAEs observed

Most common treatment-emergent adverse events (TEAEs):

• Fatigue (42.2%) was the most common TEAE in US Phase 1 study

• In JUPITER-02, 11.6% discontinued treatment due to AEs vs 4.9% in placebo arm

Distinctive safety features:

• Lacks vascular toxicity seen with pembrolizumab in NPC patients

• Fatal TEAEs occurred in 4.2% of patients in US Phase 1 study, none related to toripalimab per investigators

Management considerations:

• Appropriate patient selection and monitoring remain essential

• Standard management protocols for PD-1 inhibitor-associated irAEs appear effective

• Lower incidence of certain toxicities (e.g., vascular) may influence agent selection in specific indications

What are the optimal laboratory techniques for measuring PD-1 receptor occupancy and anti-drug antibodies against toripalimab?

PD-1 Receptor Occupancy Measurement:

• Flow cytometry-based methods:

  • Used in clinical studies to measure PD-1 receptor occupancy on CD4+ and CD8+ T cells

  • Complete occupancy defined as >80% saturation of available receptors

  • Methodology includes:

    • Isolation of PBMCs from whole blood

    • Staining with fluorescently-labeled anti-PD-1 antibodies that bind to different epitopes than toripalimab

    • Quantification of free vs. occupied receptors

• Competitive binding assays:

  • Used to assess receptor occupancy in presence of toripalimab

  • Employs labeled competing antibodies that bind to distinct or overlapping epitopes

Anti-Drug Antibody (ADA) Detection:

• Bridging ELISA methodology:

  • Most commonly used method in toripalimab clinical trials

  • Typically employs a multi-tiered approach:

    • Screening assay (identifies potential positives)

    • Confirmation assay (verifies specificity)

    • Titration assay (quantifies antibody levels)

• Statistical considerations for ADA analysis:

  • Classification of ADA responses as treatment-induced (negative at baseline, positive after treatment) or treatment-enhanced (positive at baseline with ≥4-fold increase in titer)

  • Impact assessment requires correlation with PK parameters and clinical outcomes

• Neutralizing antibody detection:

  • Cell-based assays to determine if ADAs neutralize toripalimab activity

  • Important for distinguishing between binding and functionally relevant ADAs

These methods require careful validation to ensure sensitivity, specificity, and reproducibility, particularly given toripalimab's relatively low immunogenicity profile.

How should researchers design combination studies with toripalimab to maximize synergistic effects with other cancer therapies?

Designing effective combination studies with toripalimab requires strategic consideration of multiple factors:

Rational combination selection:

• Complementary mechanisms of action:

  • Anti-CTLA-4 (e.g., HBM4003): Targets different checkpoint, enhances Treg depletion

  • Chemotherapy: Induces immunogenic cell death, enhances antigen presentation

  • Targeted therapies: Consider combinations targeting MAPK, PI3K-Akt pathways based on genomic findings

• Sequential vs. concurrent administration:

  • Most protocols use concurrent administration (e.g., toripalimab 240 mg with chemotherapy)

  • Consider sequential approaches for combinations with significant overlapping toxicities

Study design considerations:

• Dose optimization:

  • Implement dose-finding phase (e.g., 3+3 design) for novel combinations

  • Evaluate multiple dose levels of combination agent while maintaining standard toripalimab dose (240 mg Q3W)

• Patient stratification factors:

  • PD-L1 expression status (TPS/CPS scores)

  • TMB and specific genetic alterations (e.g., focal adhesion-PI3K-Akt pathway mutations)

  • Tumor microenvironment characteristics (e.g., Treg/CD4+ ratio)

• Biomarker-driven approaches:

  • Include mandatory tumor biopsies (pre-treatment and on-treatment)

  • Implement multiplex immunofluorescence staining to assess T cell infiltration

  • Analyze circulating cytokines (IFN-γ, TNF-α, IL-2) as pharmacodynamic markers

Efficacy endpoints:

• Primary: ORR, PFS, OS based on study phase

• Secondary: DCR, DOR, biomarker correlations

• Consider immune-related response criteria alongside RECIST v1.1

Example design framework based on successful studies:

• Phase 1: Dose-escalation (part A) followed by indication-specific cohort expansion (part B)

• Phase 2/3: Randomized design comparing toripalimab combination vs. standard of care with stratification by key biomarkers

What methods are most effective for analyzing toripalimab's binding to the FG loop of PD-1 and its impact on downstream signaling?

To effectively analyze toripalimab's binding to the FG loop of PD-1 and subsequent signaling effects, researchers should employ multiple complementary approaches:

Structural binding analysis:

• Surface Plasmon Resonance (SPR):

  • Gold standard for determining binding affinity and kinetics

  • Used to establish toripalimab's 12-fold higher binding affinity to PD-1 compared to pembrolizumab

  • Provides association/dissociation rates and equilibrium dissociation constants (KD)

• X-ray crystallography:

  • Reveals precise binding epitopes and structural interactions

  • Can confirm specific interactions with the FG loop of PD-1

  • Enables visualization of conformational changes upon binding

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Maps regions of conformational change upon antibody binding

  • Useful for comparing binding profiles of different anti-PD-1 antibodies

Signaling pathway analysis:

• SHP1/SHP2 recruitment assays:

  • Jurkat T cell-based assays with ectopic PD-1 expression

  • Quantify recruitment of these negative regulators after PD-1 engagement

  • Western blot or phospho-specific flow cytometry to measure phosphorylation events

• Transcriptomic analysis:

  • RNA-seq of treated vs. untreated cells to identify differentially expressed genes

  • Revealed toripalimab induces unique genes in IFN-γ and immune cell pathways

  • Can be performed in cell lines, PBMCs, or dissociated tumor cells

• Cytokine profiling:

  • Multiplex Luminex assays to analyze secreted cytokines

  • Compare profiles across different anti-PD-1 antibodies at various concentrations

  • Group cytokines by function (Th1, Th2, Th17, etc.) for comprehensive analysis

Functional validation:

• T cell activation assays:

  • Measure CD69/CD25 expression, proliferation (Ki-67), and cytokine production

  • Particularly focused on IFN-γ, TNF-α, and IL-2 secretion

  • Compare responses between toripalimab and other PD-1 inhibitors

• Ex vivo tumor models:

  • Using dissociated tumor cells from treatment-naïve patients

  • Allows comparison of activation kinetics and gene expression patterns

  • More physiologically relevant than cell lines

These methodological approaches together provide comprehensive insights into toripalimab's unique binding characteristics and subsequent immunological effects that differentiate it from other PD-1 inhibitors.

How can researchers accurately assess toripalimab's efficacy in tumors with heterogeneous PD-L1 expression?

Accurately assessing toripalimab's efficacy in tumors with heterogeneous PD-L1 expression requires sophisticated methodological approaches:

Multidimensional PD-L1 assessment:

• Multiple scoring systems:

  • Tumor Proportion Score (TPS): Percentage of tumor cells expressing PD-L1

  • Combined Positive Score (CPS): Includes tumor cells, lymphocytes, and macrophages

  • Use both metrics for comprehensive characterization

• Spatial heterogeneity analysis:

  • Multiple tumor region sampling (≥3 regions recommended)

  • Whole-slide digital pathology with automated quantification

  • Report both mean expression and coefficient of variation

• Temporal heterogeneity considerations:

  • Compare pre-treatment vs. on-treatment biopsies

  • Assess PD-L1 induction after initial therapy cycles

Advanced biomarker integration:

• Multiplex immunofluorescence staining:

  • Simultaneously assess PD-L1, CD8+ T cells, and other immune populations

  • Quantify cell-cell spatial relationships and proximity analyses

  • Calculate Treg/CD4+ ratios as independent predictive factors

• Genomic correlates:

  • Stratify by TMB status alongside PD-L1 expression

  • Analyze focal adhesion-PI3K-Akt signaling pathway mutations

  • Integrate these genomic features with PD-L1 heterogeneity metrics

Clinical trial design considerations:

• Prospective stratification:

  • Prespecified analysis of outcomes by PD-L1 status

  • Include PD-L1 negative, low, and high expression cohorts

  • Adequate powering for interaction analyses

• Statistical approaches:

  • Test for treatment-biomarker interactions using appropriate models

  • Consider PD-L1 as both categorical and continuous variable

  • Use forest plots to visualize efficacy across PD-L1 subgroups

• Post-hoc analyses:

  • Examine outcomes across PD-L1 expression continuum

  • Identify potential threshold effects specific to toripalimab

  • Compare with historical controls from other PD-1 inhibitors

Research has shown that toripalimab maintains efficacy regardless of PD-L1 status in multiple indications, including nasopharyngeal carcinoma, NSCLC, and esophageal squamous cell carcinoma . These methodological approaches help elucidate the mechanisms behind this broader efficacy profile compared to other PD-1 inhibitors.

What are the emerging applications of toripalimab in novel cancer types and treatment settings?

Toripalimab research is expanding into several promising new areas:

• Rare and underserved cancer types:

  • Small cell carcinoma of the urinary system: Currently being investigated in combination with etoposide and platinum-based chemotherapy

  • Neuroendocrine tumors: Included in multi-cohort expansion studies

  • Mucosal melanoma: Showing promising 40% ORR in anti-PD-1/PD-L1 treatment-naïve patients

• Earlier disease settings:

  • Adjuvant therapy following surgical resection

  • Consolidation treatment after chemoradiation in locally advanced disease

  • Neoadjuvant applications to improve surgical outcomes

• Biomarker-selected populations:

  • Patients with focal adhesion-PI3K-Akt signaling pathway mutations

  • Exploration in MSI-H/dMMR tumors across multiple cancer types

  • Targeting high TMB populations regardless of tumor origin

• Novel combination approaches:

  • With bi-specific antibodies that engage T cells directly to cancer cells

  • Together with targeted therapies based on tumor-specific mutations

  • In triplet regimens combining immunotherapy, targeted therapy, and chemotherapy

• Special populations:

  • Pediatric indications (studies including patients ≥12 years)

  • Immunocompromised patients typically excluded from immunotherapy trials

  • Patients with brain metastases or leptomeningeal disease